Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The Respiratory syncytial virus small hydrophobic protein (SH protein) is a short, type II transmembrane protein (64 amino acids) encoded by the RSV genome. The protein oligomerizes into pentamers and forms pH-dependent, acid-activated ion channels (viroporin activity) in host cell membranes, specifically displaying proton and monovalent cation flux. SH protein suppresses apoptosis via inhibition of TNF-α signaling, contributes to immune evasion and RSV pathogenesis, and modulates host cytokine responses such as IL-1β through inflammasome activation. Its absence does not block virus replication or syncytium formation in vitro, but leads to attenuated viral phenotype and diminished pathogenicity in vivo, including reduced lung viral titers and enhanced immune activation. SH accumulates at the Golgi apparatus in infected cells and may facilitate virus release by modifying the secretory pathway. The SH protein is a validated antiviral drug target, with small-molecule inhibitors able to block its channel activity.
Inhibitors such as pyronin B block SH-mediated ion channel activity in viral and host membranes.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Respiratory syncytial virus small hydrophobic protein (SH protein).